Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 44, Issue 1, 2007, Pages 35-40

  Heyman, Melvin B ^a   Zhang, Weijiang ^b   Huang, Bidan ^c   Chiu, Yi Lin ^c   Amer, Fouad ^b   Winter, Harland S ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c ABBOTT LABORATORIES   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Esophagus; Intraesophageal pH probe; Proton pump inhibitor; Toddler

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERGASTRINEMIA; INFANT; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; UNITED STATES; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; CHILD, PRESCHOOL; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; MALE; PROTON PUMPS;

EID: 33846113432     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000242556.57434.2e     Document Type: Article

References (18)

1. Nelson S, Chen E, Syniar G, et al. Prevalence of symptoms of gastroesophageal reflux during infancy: a pediatric practice-based survey. Arch Pediatr Adolesc Med 1997;151:569-72.
2. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Arch Pediatr Adolesc Med 2000;154:150-4.
3. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S300-7.
4. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S308-18.
5. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000;32:660-6.
6. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1397-402.
7. Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S327-35.
8. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediat 2000;137:800-7.
9. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32 (Suppl 2):S1-31.
10. Gunasekaran TS, Hassall E. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123:148-154.
11. Gremse D, Winter H, Tolia V, Gunasekaran T, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S319-26.
12. Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics of orally administered omeprazole in children. Am J Gastroenterol 2000;95:3103-6.
13. Tran A, Rey E, Pons G, Pariente-Khayat A, et al. Pharmacokinetic- pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002;71:359-67.
14. Karol M. Drug Metabolism Report No. 32. Overview and Summary of the Human Pharmacokinetics and Biopharmaceutics of Lansoprazole. Abbott Laboratories Division 46 Report No. R&D/92/393, 1992.
15. Freston J, Rose P, Heller C, et al. Safety profile of lansoprazole: the US clinical trial experience. Drug Safety 1999;20:195-205.
16. Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990;19:141-53.
17. Madrazo-de la Garza A, Dibildox M, Vargas A, et al. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr 2003;36: 261-265.
18. Dohil R, Fidler M, Barshop B, et al. Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Pediatr Nephrol 2005;20:1786-93.